SnagRx vs bmiMD: Pricing, pharmacies, and clinician access compared
Quick verdict: For cost-driven patients seeking a locked-in compounded semaglutide price across titration, SnagRx is focused on predictable annual-plan pricing; bmiMD is focused on multi-month billing tiers for compounded tirzepatide and around-the-clock clinician access. This article compares SnagRx vs bmiMD on pricing, medication type, clinician availability, pharmacy sourcing, and shipping.
See SnagRx semaglutide plans from $69/mo
How SnagRx vs bmiMD differ on price and billing
SnagRx advertises compounded semaglutide from $69/month on a 12-month plan and $99/month month-to-month. bmiMD lists compounded tirzepatide at tiered monthly rates: $179 month-to-month, $159 for three months, $149 for six months, and $139 for a 12-month plan. Both require a longer commitment to reach the lowest advertised monthly rate.
View bmiMD tirzepatide billing options
Medication type and compounding status
SnagRx emphasizes compounded semaglutide and compounded tirzepatide options with pricing examples focused on semaglutide from $69/month and tirzepatide from $119/month on the annual plan. bmiMD focuses on compounded tirzepatide with multiple subscription lengths. Importantly, both providers state that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Clinician review and ongoing access
SnagRx uses a clinician network called OpenLoop Health and states clinicians typically review intake within five hours and always within 24. bmiMD highlights 24/7 clinician access with online refills and delivery. If clinician availability or speed of review matters, SnagRx promotes a rapid clinician review window while bmiMD highlights around-the-clock access.
Pharmacy sourcing and shipping
SnagRx names its four US 503A partner pharmacies and promises next-day UPS or FedEx temperature-controlled shipping. bmiMD states medications are prepared in state-licensed pharmacies and independently verified in FDA- and DEA-registered labs, and offers free shipping on subscription orders. Both claim reliable delivery but emphasize different sourcing details.
Key differences at a glance
| Criteria | SnagRx | bmiMD |
|---|---|---|
| Primary advertised medication | Compounded semaglutide (from $69/mo on 12-month plan) | Compounded tirzepatide (from $139/mo on 12-month plan) |
| Lowest monthly rate requires | 12-month plan for $69 semaglutide or $119 tirzepatide | 12-month plan to reach $139/mo |
| Price behavior during titration | Price locked flat at every dose and at renewal | Same price at every dose for chosen plan length |
| Clinician model | OpenLoop Health clinician network; typical review within five hours | 24/7 clinician access promoted |
| Pharmacy and verification | Named US 503A compounding pharmacies; next-day shipping | State-licensed pharmacies; independent lab verification; free subscription shipping |
Other practical differences and trade offs
SnagRx highlights a flat locked-in rate for the life of treatment on the plan purchased and names its four 503A partner pharmacies. SnagRx also states a full refund if a prescription is declined and mentions a 6-month weight-loss guarantee with terms. bmiMD emphasizes multiple billing lengths with lower long-term monthly equivalents and a claim of a 100 percent refundable policy if not eligible for the program. Both emphasize that compounded products are not FDA-approved.
Check SnagRx eligibility and pricing details
What the sources do not supply
Neither source supplies independent clinical outcome data comparing medications, state-by-state eligibility details beyond general statements, or definitive quality metrics that replace the regulatory note that compounded medications are not FDA-approved. Verify the providers statements directly if these details matter to you.
Confirm bmiMD plan terms and shipping
Start SnagRx intake for semaglutide or tirzepatide
Conclusion: Choose based on price structure or clinician access
SnagRx vs bmiMD contrasts a price-locked, named-pharmacy approach for compounded semaglutide with a focus on bottom-end annual pricing versus bmiMD’s multi-length billing tiers, 24/7 clinician access, and lab verification claims for compounded tirzepatide. Both use compounded medications that are not FDA-approved.
Choose SnagRx if you want an annual-plan rate-locked price for compounded semaglutide and named US 503A pharmacy partners. Choose bmiMD if you prefer tiered multi-month billing for compounded tirzepatide and 24/7 clinician access, with subscription free shipping.